The incidence of pulmonary infections caused by Mycobacterium abscessus is increasing year by year,and its high level of resistance to most antibiotics,as well as to first-line anti-tuberculosis drugs,makes the treatment difficult.Not only that,the long-term combination of antimicrobial drugs has led to an increasing incidence of adverse reactions.Omadacycline,a new semi-synthetic tetracycline,has achieved good efficacy in many case reports of Mycobacterium abscessus infections due to its good pharmacokinetic properties,relatively good safety,and high concentration in the lungs.This article elaborates on the current status of drug resistance and treatment options for Mycobacterium abscessus,the pharmaceutical characteristics of omadacycline,and the in vitro activity and clinical application of omadacycline in the treatment of lung disease caused by Mycobacterium abscessus,providing a certain reference for future research and treatment.
维普
万方数据